- 1 Heterogeneity of the placenta in health and disease explored through integrated
- 2 histology, gene expression and modelling
- Hannah Ee Juen Yong^{1,2*}, Kasia Maksym^{3,4*}, Muhammad Ashraf Bin Yusoff³, Esteban 3
- Salazar-Petres¹, Tatiana Nazarenko^{3,5}, Alexey Zaikin^{3,5}, Anna L David^{3,4,6}, Sara L 4
- 5 Hillman^{3,4}+, Amanda N. Sferruzzi-Perri¹+
- 7 *contributed equally; joint first author
- 8 +contributed equally; joint last and corresponding author
- 10 ¹Centre for Trophoblast Research,
- Department of Physiology, Development and Neuroscience 11
- University of Cambridge 12
- Cambridge UK 13
- CB2 3EG 14

9

15

19

29

- 16 ²Singapore Institute for Clinical Sciences,
- 17 Agency for Science, Technology and Research,
- Singapore 18
- ³ Elizabeth Gareth Anderson Institute for Women's Health, 20
- 21 University College London,
- 22 84-86 Chenies Mews, London UK
- 23 WC1E 6HU
- 24 ⁴ Fetal Medicine Unit
- 25 Elizabeth Gareth Anderson Wing,
- 26 University College Hospitals NHS Trust,
- 27 25 Grafton Way, London UK
- WC1E 6DB 28
- ⁵ Department of Mathematics, 30
- 31 University College London,
- 32 London UK

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 WC1E 6AE 34 ⁶ National Institute for Health Research University College London Hospitals Biomedical 35 Research Centre, 149 Tottenham Court Road, London W1T 7DN 36 37 38 Correspondence: 39 Amanda Sferruzzi-Perri (ans48@cam.ac.uk) 40 Sara Hillman (sara.hillman@ucl.ac.uk) 41

Abstract:

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

Fetal growth restriction (FGR) is a leading cause of perinatal morbidity and mortality. Altered placental formation and functional capacity are major contributors to FGR pathogenesis. Relating placental structure to function across the placenta in healthy and FGR pregnancies remains largely unexplored but could improve understanding of placental diseases. We investigated integration of these parameters spatially in the term human placenta using predictive modelling. Systematic sampling was able to overcome heterogeneity in placental morphological and molecular features. Defects in villous development, elevated fibrosis, and reduced expression of growth and functional marker genes (IGF2, VEGA, SLC38A1, SLC2A3) were seen in age-matched term FGR versus healthy control placentas. Characteristic histopathological changes with specific accompanying molecular signatures could be integrated through computational modelling to predict if the placenta came from a healthy or FGR pregnancy. Our findings yield new insights into the spatial relationship between placental structure and function and the aetiology of FGR.

Key words: Placenta, FGR, modelling, morphology, growth genes, transport

Introduction:

The human placenta is a highly specialized organ in pregnancy, whereby normal functioning is critical to fetal development and long-term health. By acting as a functional interface between the maternal and fetal circulation, it is responsible for maternal-fetal substrate exchange, protects the fetus from immune rejection by the mother and secretes hormones, which maintain pregnancy and promote healthy fetal growth and development^{1,2}. This complex organ is structurally heterogeneous, not only in terms of its broad spatial macroscopic characteristics with multiple cotyledons and vascular supply, but also at the microscopic level of the villous tree and trophoblast. Even in pregnancies that deliver at term without any apparent pathology, novel techniques such as micro-CT are now describing the large degree of heterogeneity of vascular density and branching in the placenta³. In addition, computational models have predicted that local heterogeneity in placental vascular structure can have major impacts on the resistance of the feto-placental circulation and placental dysfunction⁴. Investigating the spatial relationships between changes in gene expression and structural differences in the placenta is important, so that we may better elucidate the potential functional effect of placental pathology in obstetric disease.

Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality. The risk of *in utero* or neonatal death is especially high amongst growth restricted fetuses and neonates who are commonly born preterm ⁵. In some regions of the world, FGR and prematurity account for 80% of neonatal deaths⁶. FGR is diagnosed when a fetus fails to reach their genetically predefined growth potential and is often identified by feto-placental ultrasound features (such as increased umbilical artery resistance to blood flow), and subsequently confirmed through placental histopathology⁷. The gestational age at diagnosis is used to further subdivide FGR into early-onset, detected before 32 weeks of gestation, and late-onset according to international consensus⁸. Neonates born following FGR have an increased risk of developing health problems, both in the immediate postnatal period including low blood sugars and poor temperature regulation and feeding, but also in later adult life in the form of cardiovascular and metabolic disease^{9,10}. Management of pregnancies affected by FGR can be challenging, as timing of delivery has to be judged well, to balance the hazards of preterm birth against the risks of irreversible damage secondary to intrauterine hypoxia and nutritional deficiency or even stillbirth¹¹.

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

The placenta of FGR pregnancies is characterized by reduced syncytiotrophoblast surface area, increased thickness of the exchange barrier formed by the trophoblast and fetal capillary endothelium and an increase in placental apoptosis¹²⁻¹⁵. Whilst it is recognized that there are key mediators of fetal growth that are influenced by placental function including but not limited to transfer of gases¹⁶, glucose^{17,18}, lipids¹⁹ and amino acids^{18,20}, understanding the mechanisms through which placental histological changes might be affecting these pathways remains a challenge. Nuanced, integrated investigations will better delineate the underlying functional mechanisms related to the histological changes observed in the placenta. Experimental animal data has highlighted central roles that certain structural and functional changes play in the placenta to fetal growth outcomes²¹⁻²⁵. However, data on how structure *and* molecular changes together impact on function and on each other, even in the form of nutrient transporter expression, are scarce or not available for the human placenta^{26,27}.

Better understanding of how placental structure relates to functional capacity is further optimized through robust placental sampling protocols. Methodological errors arise from differences in sampling and/or tissue processing, which has previously hampered the reproducibility and possible extrapolation of placental studies^{28,29}. Systematic uniform random sampling involves random selection of the first sampling site, with subsequent sites dictated by a pre-made sampling interval. This method is recommended to ensure representative and unbiased sampling of the placenta^{29,30}. It is a simple method, allowing for even coverage of the placenta and ensures that all sites can only be selected once²⁹. In practice, however, systematic uniform random sampling has limitations. Firstly, its lack of bias may be compromised if the pre-determined sampling interval coincides with a natural pattern existent in the placenta³⁰. Secondly, placentae templates designed for systematic uniform random sampling assume all placentas to be roughly circular in shape, with central umbilical cord insertion. This assumption of a uniform shape and cord insertion however is incorrect. Although studies do show that mean placental chorionic shape at term is round, deviations in placental shape are associated with reduced placental efficiency³¹. In addition, the site of umbilical cord insertion appears to be related to placental function, with a marginal cord insertion near the outer boundary of the placenta being associated with a more asymmetric chorionic vessel structure³², which has been associated with FGR, stillbirth and neonatal death³³.

While analysis of single sites may miss important histopathological and functional changes, multiple site collection poses analytical challenges, and methods may still fail to identify

critical differences within placentas affected by pathology, such as FGR. Statistical modelling allows for the exploration and integration of multiple data points from the same sample to provide more accurate interpretation of functional consequences. Moreover, the use of modelling to predict regional and disease state differences has high translational potential, for example providing an explanation for why the pregnancy was compromised and which baby may benefit the most from early health monitoring and/or postnatal intervention. With this study we therefore, firstly sought to better understand if systematic uniform random sampling methods could be optimised to the challenges that FGR placentas pose. Secondly, we sought to characterise the degree of detailed histological and molecular heterogeneity between multiple samples in healthy and FGR placentas and to examine potential links between histological changes and the expression of genes involved in placental formation, transport, and transcriptional regulation, and their relationships with fetal growth/pregnancy outcome. Finally, in a proof of principle approach, we integrated these changes into a novel analysis model to better delineate the significance of the placenta in health and disease.

Results:

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

Patient characteristics

We matched FGR cases and controls for maternal age, booking BMI, mode of delivery and infant sex (Table 1) with expanded clinical data available (Supplementary Table 1). Nonetheless, several significant differences in clinical characteristics were still observed. FGR cases were more likely to be non-White and delivered infants with lower birth and placental weights about a week earlier, although all delivered at term (>36⁺⁶ weeks of gestation).

Table 1: Patient characteristics.

Characteristics	Control (N=9)	FGR (N=7)	P-value
Maternal age	34.44 ± 1.84	32.00 ± 1.16	0.339
Maternal ethnicity	8 white, 1 non-white	2 white, 5 non-white	0.035
Booking BMI (kg/m ²)	24.67 ± 1.51	24.47 ± 2.75	0.946
Mode of delivery	4 vaginal deliveries, 5 caesarean sections	2 vaginal deliveries, 5 caesarean sections,	0.620
Gestational age at delivery (weeks)	39.14 (39.07 – 39.79)	38.29 (37.29 – 39.00)	0.006
Infant sex	4F, 5M	2F, 5M	0.633
Infant birthweight (kg)	3.53 ± 0.13	2.33 ± 0.18	< 0.001

Placental weight (g)	478.9 ± 16.6	340.7 ± 31.0	0.001
----------------------	------------------	------------------	-------

Data are presented as mean ± SEM and were analysed by Student's t test or Mann-Whitney U test. Categorical data were analysed by 2 X 2 contingency table with Fisher's Exact Test. BMI, body mass index; F, female; M, male.

Stereological analysis of placental morphology

151

152

153 154

155

156

157

158 159

160

161

162

163

164

165

166

167

168

Comparing stereological findings by sampling site within the FGR or control groups showed no significant differences between samples taken from the central and peripheral regions of the placenta (Supplementary Table 2). Hence, we averaged the data of the central and peripheral regions of each placenta to compare by pathology (Table 2). Taking into consideration a false discovery rate of 5% for multiple testing, FGR placentas had significantly lower volume densities of intermediate villi, syncytial knots and higher volume densities fibrosis and capillaries. Once placental weight was accounted for, FGR cases showed decreased volumes of intervillous spaces, intermediate villi, terminal villi, syncytial knots, trophoblast and stromal components, and increased volume of fibrosis compared to control placentas. There were no differences in any measure of barrier thickness, surface area, surface densities and diffusion capacities between FGR and control placentas; except that FGR placentas had a decreased villi surface area.

Table 2: Morphological differences in the placenta by pathology

169

	Control (N=9)	FGR (N=7)	P-value
			(^FDR)
Volume density (cm³/g)			
Intervillous space	0.37±0.01	0.36±0.02	0.447
Stem villi	0.06±0.01	0.06±0.01	0.895
Intermediate villi	0.12±0.01	0.08±0.01	0.008*
Terminal villi	0.42±0.02	0.4±0.03	0.474
Syncytial knots	0.02±0.00	0.01±0.00	0.002*
Fibrosis	0.01±0.01	0.1±0.02	0.001*
Trophoblast	0.32±0.01	0.34±0.03	0.583
Stromal	0.55±0.02	0.45±0.05	0.058
Capillary	0.13±0.01	0.21±0.03	0.016*
Volume (cm ³)			
Intervillous space	179.73±9.45	119.44±10.77	0.001*
Stem villi	27.83±3.2	20.17±4.25	0.163
Intermediate villi	55.4±4.41	25.48±2.43	<0.001*
Terminal villi	200.73±10.54	135.3±16.23	0.003*
Syncytial knots	8.39±0.78	2.44±0.71	<0.001*
Fibrosis	5.88±3.24	37.02±7.43	0.001*
Trophoblast	153.5±6.83	114.7±13.69	0.017*
Stromal	263.09±15.46	153.23±21.66	0.001*
Capillary	62.3±5.04	72.78±13.76	0.445
Barrier thickness (µm)			
Arithmetic mean	2.83±0.08	2.85±0.18	0.912
Harmonic mean	2.14±0.07	2.24±0.14	0.500
Thickness uniformity index (a	1.32±0.01	1.48±0.08	0.044
measure of thickness variability)			
Surface density (cm ² /cm ³)			
Villi	610.45±23.85	630.28±44.68	0.683
Fetal capillary	298.26±19.81	401.92±48.29	0.048
Surface area (m²)			

Villi	11.68±2.88	10.59±1.55	0.009*		
Fetal capillary	6.27±1.7	6.89±1.23	0.576		
Theoretical diffusion capacity	95.29±4.86	70.26±11.5	0.047		
(cm ² /min/kPa)					
Specific diffusion capacity	27.2±1.49	29.47±3.99	0.567		
(cm ² /min/kPa/g)					

Data presented as mean \pm SEM and analysed by t test with FDR (false discovery correction) correction at 5%. * denotes significant findings that passed the 5% FDR.

Placental expression of growth factors and nutrient transporters

170

171

172

173

174

175

176

177

178

179

180

181

182


183

184

185

186

We also evaluated relative mRNA expression of selected growth factors and nutrient transporters (Figure 1) that have been previously implicated in transcriptional control or with compromised fetal growth in humans and animal models of FGR³⁴⁻³⁹. Placental *IGF2*, *SLC2A3* and SLC38A1 expression was significantly lower for FGR versus controls, regardless of sampling location (Figures 1A, 2D and 2E). VEGFA expression was significantly lower in the peripheral region as compared to the central region of FGR placentas, while no statistical difference was identified in the central region between cases and controls (Figure 1B). Only SLC2A1 expression was significantly increased in FGR placenta as compared to controls, independent of sampling location (Figure 1C). No differences in mRNA expression of and SLC38A2 were observed between FGR and control placentas or by sampling location (Figure 1F). In controls, placental HNF1A expression was higher in the peripheral region as compared to the central region (Figure 1G), but no differences were identified for FGR.



189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Figure 1: Relative mRNA expression of selected growth factors and nutrient transporters in control and FGR placentas. Expression of growth factors (IGF2, VEGFA), and transporters (SLC2A1, SLC2A3, SLC38A1, SLC38A2 and the transcription factor HNF1A), were evaluated by qPCR. A total of 3 outliers were excluded; 1 control peripheral value for VEGFA, and 1 control central value and 1 control peripheral value for HNF1A. Data are presented with individual data points with mean \pm SEM and analysed with two-way ANOVA, followed by Sidak's post hoc test for multiple comparisons. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Associations between placental morphology and expression of functional genes

We next evaluated relationships between placental morphology and the expression of growth factor and nutrient transporter genes within the different sampling sites, and between control and FGR groups using Pearson's r coefficient (Figure 2). In FGR placentas, several inverse correlations were identified between expression of IGF2, VEGFA, SLC38A1 and SLC2A3 and the volume of terminal villi, trophoblast, and capillary volume predominantly in the peripheral region of FGR placentas. Inverse correlations with fibrosis volume were also observed for expression IGF2, VEGFA, SLC38A1 and SLC2A3 in the central region of FGR placentas. Additionally, the relative expression of IGF2, VEGFA, SLC38A1 and SLC2A3 genes was inversely correlated with barrier thickness uniformity index and both maternal blood spaces and fetal capillaries surface densities in the FGR placenta (central and peripheral sites), although no significant correlations were detected for the control placenta. Moreover, the expression of IGF2, SLC38A1 and SLC2A3 genes negatively correlated with both theoretical and specific diffusion capacity in FGR, but not control placentas. In contrast, FGR expression of HNF1A showed a positive correlation with specific diffusion capacity in the peripheral region. Positive correlations between the expression of all genes measured and fibrosis and stromal volumes were found for the peripheral region of control placentas, but not FGR placentas. Positive relationships were also seen for expression of VEGFA and HNF1A with the stem villi volume in central sites of control placentas.




Figure 2. Correlations between stereological parameters and the relative expression of functional genes in the placenta. Pearson's r coefficient was plotted and used to indicate strength of relationship between data (0: low, 1: high) and direction of correlation (+ sign: direct correlation and – sign: inverse correlation). Analysis was performed on each sampling site and experimental group (control and FGR) separately. Sample size was 36 for control and 24 for FGR. *: p < 0.05, correlation is statistically significant.

Predictive modelling

217 218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

To evaluate the information gained from different placental regions/sampling sites (only peripheral, only central, or both together) and data types (only stereological data, only qPCR data or both together), we considered all their possible combinations using predictive modelling (construction of classifiers that would make it possible to distinguish patients in the control group from patients with FGR). As predictive modelling was carried out using three machine learning (ML) methods; xgbTree, glmnet and nnet, this resulted in 27 models for consideration. The binary outcome of FGR was used as an outcome with chosen set of features (only stereological data, only qPCR data, both data types together) used as predictors. The predictive performance of each model was assessed using a leave-one-out cross-validation (LOOCV) scheme: the prediction was made for each patient (with all measurements) by excluding (withholding) it from the dataset, training the classifier on the remaining (independent) samples, and then generating predictions for the withheld samples using the trained model. Using predictions on the training subset (on each round of LOOCV procedures), the best threshold (corresponding to the best sum of sensitivity plus specificity) distinguishing

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

controls from FGR cases was found and a binary result was calculated for each withheld sample (1 indicated FGR if the prediction was above the threshold, and 0 indicated control if it was below the threshold). Through all rounds, LOOCV procedure binary results were collected for withheld samples and performance was assessed using by these sets of predictions. Performance was estimated using areas under the ROC curve (AUCs) in 2 ways: "AUC for all samples" and "AUC for all patients", as described in Methods. For each combination of "placenta part + type of measurement + ML model" two such AUC values were obtained. Full results of these analyses can be found in Table 3 (in addition, we provide a complete table of errors for each patient in Supplementary Table 3). For a simplified visualization of these results, we considered the distributions of results (AUCs) of different types of ML models on different types of data obtained in different parts of the placenta for all patients and for all their samples separately (Figure 3). This plot clearly shows that among the considered models, the best are those based on measurements performed on the peripheral parts of the placenta and using stereological and qPCR data together. As shown in Table 3, the best model was found to be *nnet*, i.e., the model using simple artificial neural networks for a classification. This model gave the best result for both "AUC for all samples" (0.979) and "AUC for all patients" (0.917). By considering the stereological and qPCR data separately, the stereological data showed a greater predictive power than the qPCR data (Figure 3, for all variants), which, may be due to the clearly different interdependences of the stereological parameters of the control group and the FGR group (the most significant interdependences are presented in Supplementary Figure 1). However, a combination of stereology and qPCR data works better than just stereology for analyses on peripheral parts of the placenta (Figure 3). The results obtained on the central parts of the placenta were lower than the results obtained on both parts of the placenta or only on the peripheral (boxplots for the central parts are slightly lower than the other options). Moreover, results using only peripheral parts were better than using a combination of both parts. Thus, the best model would be that based on measures made on the peripheral parts of the placenta using stereological and qPCR data together.

Table 3: Predictive modelling results using different machine learning methods.

269

270

271

272

273

274

Peripheral & Central											
	St	ereology			qPCR		Stereology & qPCR				
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	nnet			
AUC for all samples	0.899	0.913	0.927	0.705	0.733	0.719	0.875	0.92	0.948		
AUC for all patients	0.611	0.861	0.917	0.639	0.528	0.528	0.694	0.861	0.917		
Peripheral											
	Stereology				qPCR			Stereology & qPCR			
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet		
AUC for all samples	0.903	0.938	0.924	0.681	0.694	0.681	0.819	0.938	0.979		
AUC for all patients	0.861	0.917	0.861	0.556	0.556	0.556	0.778	0.917	0.917		
				Central							
	St	ereology			qPCR		Stereo	Stereology & qPCR			
	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet		
AUC for all samples	0.889	0.903	0.903	0.722	0.694	0.722	0.826	0.889	0.889		
AUC for all patients	0.778	0.861	0.861	0.611	0.611	0.611	0.722	0.861	0.806		

Results for each combination of "placenta part + type of measurement + ML model" The best version of the model is *nnet* model (highlighted in bold) on peripheral parts of placenta using stereological and qPCR data together. In this case, "AUC for all patients" = 0.917 (corresponding to an error for just one patient-case in a sample of 15 patients: 9 controls and 6 FGR), and "AUC for all samples" = 0.979 (corresponding to an error for only one measurement, a FGR in a set of 15*4 samples: 9*4 control samples and 6*4 FGR samples). A complete table of errors is given in Supplementary Table 3.




Figure 3: Distributions of AUCs, i.e., the performance results of different types of models on different types of data obtained on different parts of the placenta for all patients and for all their measurements separately.

Discussion

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

There was no significant variability in the morphological features of the placenta within and between the peripheral and central sites of the placenta, regardless of whether they came from a healthy or FGR pregnancy. In addition, the findings indicate that alterations in placental morphology may be uniform across the placenta in late-onset FGR pregnancies without other complications, such as pre-eclampsia, that can lead to more variable histological changes across the placenta⁴⁰.

Despite established evidence that the placenta drives a number of the 'great obstetrical' syndromes, which includes FGR, the relatively poor understanding of underlying placental mechanisms makes interpretation of how they contribute to clinical presentations difficult⁴¹. Heterogeneity within the placenta is thought to be responsible for some of the difficulties in directly relating disease state to placental findings. Our results suggest that the systematic sampling technique that we used was able to overcome potential morphological spatial heterogeneity of the term placenta, whether from normal or late FGR pregnancies. Indeed,

peripheral versus central region comparisons revealed unique features in gene expression correlations and predictive modelling results. These findings enable more clinical interpretations to be made of the results and indicate that using of this sampling technique may improve reproducibility between placental studies. This analysis suggests that at least a peripheral and central sample should be taken when assessing placental function, particularly in disease states.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

Morphological differences between the control and FGR placenta are consistent with findings of others⁴², and indicate villous mal-development, with fewer mature intermediate and terminal villi and reduced villous surface area, as well as elevated fibrosis. The increased villous capillary density and reduced syncytial knots in the studied FGR placentas are novel findings and may reflect adaptive responses to hypoxic-reoxygenation events secondary to reduced utero-placental and/or feto-placental flows in FGR pregnancies⁴³⁻⁴⁵. Moreover, these beneficial changes in placental morphology may be the explanation for the FGR babies in our study reaching near full term. Hence, morphological findings provide a clue to underlying placental mechanisms that may be subject to change, with the resultant amelioration of disease and improvement to fetal outcome, if they can be enacted in utero. There is already significant interest in delivery of targeted agents to the uterine arteries to improve blood flow⁴⁶. Delivery of agents to target specific areas of pathology and functional deficit within the placenta to improve the clinical condition may also be a potential therapeutic option.

Our approach to combine morphological assessments with gene expression aimed to identify some key aetiological pathways for the pathology seen. Expression of placental IGF2, SLC2A3 and SLC38A1 was lower across the FGR placenta, correlating with volumes and other specific placental features, suggesting a global role for these molecules in placental structure and development in the presence of FGR. Indeed, *IGF2* is known to be important for the formation of the placental exchange interface in humans, among other species 38,39,47, and is expressed at lower levels in placentas showing FGR/small for gestational age in some^{48,49}, but not all studies⁵⁰. Prior work has shown that a genetic deficiency of *SLC2A3* in mice leads to FGR ³⁷ which supports our findings, but is in contrast to other work reporting an upregulation of its encoded protein in the human placenta of late-onset FGR⁵¹. Of the system A amino acid transporters expressed by the human placenta, *SLC38A1* is key for system A activity at term⁵². Other work has also shown that placental system A activity is reduced in explants prepared from term FGR placentas⁵³. VEGFA was significantly lower in the peripheral region of the

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

placenta in FGR and correlated to the following placental pathology (terminal villi, trophoblast and capillary volume) that might suggest a causal association. This is consistent with other work reporting lower placental VEGFA expression at term in late onset FGR^{54,55}, and the involvement of angiogenic factors more generally in normal and pathological pregnancies⁵⁶. Our findings also have relevance for emerging pre-clinical research in placenta-directed gene therapy for FGR, including the utility of insulin-like growth factors and angiogenic regulators⁵⁷. HNF1A was more highly expressed by the peripheral region compared with central region in healthy, but not FGR placentas. Little is known about the function of HNF1A in the placenta, although the human tissue atlas⁵⁸ indicates it is abundantly expressed by the villous syncytiotrophoblast ⁵⁹. Recent work has highlighted that *HNF1A* may regulate a large number of genes in trophoblast cells⁶⁰ and mediate metabolic changes⁶¹, which could be important for the placental support of fetal growth, more broadly.

Using a modelling approach in our discovery cohort, we demonstrated the potential of predicting outcome (control or FGR) based on stereology and qPCR data. Stereology and qPCR measurements taken from the peripheral part of the placenta, and analysed together, have the highest predictive power. To avoid any possible overfitting of the models, we did not perform any feature selection in advance for tuning of the algorithm hyperparameters. Despite this, we were able to obtain predictions with very high accuracy, as, in fact, for the best model, only one sample out of 60 (4 samples from peripheral placenta part for each of 15 patients) considered was predicted incorrectly. Indeed, this subject was one that was most likely to be misclassified in all of the tested models. Nevertheless, we found that the morphological data clearly shows separation of features for control and FGR placentas and probably, this made it possible to obtain high quality constructed models. For the present study, we used a very strict LOOCV. Whilst modelling predictions were poor when qPCR data were used alone, adding these data to the analysis of stereology data improved prediction, hence, confirming importance of qPCR data and underlying link of these data with functional features. Whilst our modelling approach shows potential, future work would benefit from utilising a larger dataset, with extremes of pathology, to validate the model.

Overall, our data add to current understanding of placental function through comprehensive sampling of healthy placentas and those affected by disease (FGR) with careful deep histological analysis, integrated with expression of genes involved in key biological pathways regulating placental function. Whilst, our modelling approach requires validation, with further

pathology analysed, it offers the promise of better diagnostic yield and novel insight into biological pathways that affect FGR pregnancies.

Material and methods:

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389


390

391

Placental tissue collection and sampling

Subjects were recruited from University College London Hospital NHS Foundation Trust, London, UK with ethics approval from the South-Central Oxford A research ethics committee (17/SC/0432). After written informed consent was obtained, term placental biopsies were collected from subjects diagnosed with late-onset FGR (n=7, FGR detected after 32 weeks' gestation and an estimated fetal weight and/or abdominal circumference below 3rd centile on population-based charts used clinically⁶²), and from control subjects with appropriately grown fetuses (n=9 birthweight >10th centile and <90th centile). Data on maternal pre-existing conditions, previous obstetric history, ultrasound examination, and pregnancy complications were collected at the time of recruitment.

Placentas were weighed and sampled within 30 minutes of delivery. Sampling sites were chosen to be representative of four central and four peripheral regions always relative to cord insertion (Figure 4A). In marginal cord insertions, the placenta was orientated with the cord anterior. Sampling then took place relative to the cord insertion as in other cases. This meant there was one site that had less tissue to sample from initially, in non-central cord insertions, but that ultimately the same amount of tissue was sampled, and that tissue selection was directly related to the cord in the same way as all other samples. For each placenta, 8 tissue biopsies (with maternal tissue and fetal chorionic plate removed) were snap frozen using liquid nitrogen or dry ice and stored at -80°C. Neighboring sampling sites were then immersion-fixed in 4% paraformaldehyde.



393 394

395

396

397

398

399

400

401

402

403

404

405

Figure 4. Diagram showing sampling of placenta (A) and main parameters measured in histological sections of placenta (B-D). (A) Dotted lines indicate where the placenta should be cut with a sterile histology knife. Red boxes with single letters indicate inner sections. Yellow boxes with double letters indicate outer sections. Green rectangles represent samples taken for RNA sampling. The central blue circle represents the umbilical cord (cut). (**B-D**) Representative histological sections of term human placenta. Stereological analysis was performed by identifying the intervillous space (IVS), stem villi (SV), intermediate villi (INTV), terminal villi (TV), fibrosis (FIB), syncytial knots (*); and under higher magnification of terminal villi, the trophoblast cell layer (#), fetal capillaries (+) and stromal cells (^). The scale bar denotes 50µm.

RNA extraction, cDNA synthesis and qPCR

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

Total RNA was extracted from n=9 control and n=6 FGR frozen placental tissues (n=1 FGR sample was not taken due to >30 minute delay in freezing this sample) using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Briefly, approximately 2mg of tissue was added to 300µl of lysis buffer and homogenized using a bead-based technique. Following treatment with proteinase K and addition of 100% ethanol, the homogenate was transferred to the spin columns, washed with supplied buffers and centrifuged to remove contaminants. Purified RNA was then eluted into RNase-free water. Quality and concentration of extracted RNA were determined by Nanodop (Thermo Fisher Scientific, Waltham, CA, USA).

Complementary DNA (cDNA) was synthesized using the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to manufacturer's instructions on a thermal cycler. Real-time PCR was performed in duplicate using TagManTM Universal Master Mix II, with UNG (Thermo Fisher Scientific) and inventoried TaqMan® gene expression assay probes with either VIC and FAM fluorophores for 5 housekeeping genes (18SrRNA, B2M, GAPDH, GUSB and YWHAZ) and 8 genes of interest (HNF1A, IGF2, SLC2A1, SLC2A3, SLC38A1, SLC38A2, SLC38A4 and VEGFA) (Table 4). Only stable housekeeping genes (18S rRNA, B2M, GADPH and YWHAZ) that showed no statistically significant differences between cases and controls were included in the housekeeper geomean calculation for normalising gene expression across samples. The relative expression of genes of interest was then calculated using the $2^{-\Delta\Delta Ct}$ method.

Table 4 Probes used for real-time PCR

Analysed genes	Gene symbol	Probe ID	Fluorophore
Housekeeping	18S rRNA	Hs99999901_s1	VIC
genes	B2M	Hs00187842_m1	VIC
	GAPDH	Hs02786624_g1	VIC
	GUSB	Hs00939627_m1	VIC
	YWHAZ	Hs01122445_g1	VIC
Genes of interest	HNF1A	Hs00167041_m1	VIC
	IGF2	Hs04188276_m1	FAM
	SLC2A1	Hs00892681_m1	FAM

SLC2A3	Hs00359840_m1	FAM
SLC38A1	Hs01562175_m1	FAM
SLC38A2	Hs01089954_m1	VIC
SLC38A4	Hs00394339_m1	FAM
VEGFA	Hs00900055_m1	FAM

Histological preparation

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

Following paraformaldehyde fixation, biopsies of 8 sites from each control (n=9) and FGR (n=7) placenta were embedded in paraffin using routine histological techniques and sectioned at 7µm thickness. Sections were rehydrated using xylene and ethanol gradients, stained with haematoxylin and eosin, dehydrated with ethanol gradients and xylene, then mounted with DPX. Slides were then scanned using a Nanozoomer digital slide scanner (Hamamatsu Photonics, Shizuoka Prefecture, Japan).

Placental stereology

Placentas were analysed blinded to the diagnosis of FGR. To perform stereological analysis in a manner similar to that performed previously⁶³; transparent lattices with test points, test lines or test arcs were superimposed onto scanned images viewed under different magnification on the NDP.view2 software (Hamamatsu Photonics). Volume densities of the intervillous space, stem villi, intermediate villi, terminal villi, syncytial knots, and fibrosis (Figure 4B-C) were estimated by point counting and a lattice of equally spaced test points arranged 4 by 4 under 10X magnification in at least 13 fields of view for a minimum of 200 measurements per section. Volume densities of the trophoblast, stroma, and fetal capillaries (Figure 4D) within villi were estimated under a similar lattice under 40X magnification in 20 fields of view per sample. Absolute placental volumes were estimated by multiplying volume densities with placental weight (g). Arithmetic barrier thickness was assessed under 100X magnification in 20 fields of view per sample and a superimposed lattice with equally spaced straight test lines, which at times, intersected fetal capillary and villous trophoblast involved in exchange. The 'measure' tool within the software was then used to determine the shortest distance between a fetal capillary and the maternal blood space, where there was an intersection. Mean harmonic barrier thickness was calculated using the inverse of mean reciprocal of each raw arithmetic barrier thickness measurement. Thickness uniformity index, as a measure of the variability in thickness across the villous membrane, was obtained from the ratio of the mean arithmetic

barrier thickness to the mean harmonic barrier thickness. Surface densities were approximated by counting chance intersections of fetal capillaries and villous trophoblast involved in exchange with superimposed test arc lines under 40X magnification. To derive surface areas, surface densities were multiplied by placental villous volume. The theoretical diffusion capacity was calculated using the total surface area for exchange (averaged surface area of fetal capillaries and villi) divided by the mean harmonic barrier thickness and multiplied by Krogh's constant for oxygen diffusion. Specific diffusion capacity was then calculated by dividing the theoretical diffusion capacity by the infant birthweight.

Predictive modelling

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

To evaluate the informativity of different placental sampling locations (only peripheral, only central or both regions together) and different data types (only stereological data, only PCR data or both types together), we studied all their possible combinations with analysis performed in R (version 4.0.2). To analyse several well-established multi-dimensional methods of data analysis, the machine learning models (xgbTree, glmnet and nnet) were implemented using caret package (version 6.0.90). All 27 models were trained with default set of hyperparameters, cross-validated on 5 folds (for a better selection of internal algorithm parameters), with seed parameter set to 123. The performance of models was assessed with receiver operating characteristic (ROC) curves using area under the curve (AUC) with 95% confidence intervals (pROC package, version 1.18.0). Results of AUCs were presented in two ways:

- All sample's AUC Calculating AUC considering all samples as independent;
- All patient's AUC Calculating AUC on patient's result's only (if all samples belonging to one patient were correctly predicted, then we assumed that a prediction for this patient was correct, if the prediction was wrong in at least one sample of the sample's patient, then it was set as wrong for this patient).

For illustration of interdependencies of features, which are presented in Supplementary Figure 1, we selected the best pairs that showed significant differences between FGR and control groups using ANOVA test after applying FDR (false discovery rate) adjustment to test's pvalues (stats package, Version 4.0.2).

Statistical analyses

Normality of data was assessed by D'Agostino-Pearson normality test. ROUT testing for outliers was used to identify any outliers, which were then excluded from the analysis. For comparisons between 2 groups, Student's t tests and Mann-Whitney U tests were performed

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

for parametric and non-parametric continuous data, respectively. Categorical data between FGR and controls were analysed by a 2 X 2 contingency table with Fisher's Exact Test. Twoway ANOVAs followed by Sidak post hoc test for multiple comparisons were used to analyse mRNA expression data by pathology and sampling location. Graphpad Prism 6.01 (Graphpad Software Inc., La Jolla, CA, USA) was used for statistical analyses. A p-value of <0.05 was considered statistically significant for clinical characteristics and mRNA expression analysis. To account for multiple testing in histological analyses, a false discovery rate correction at 5% was applied to determine statistical significance. Acknowledgements ANSP received funding for this work via an Academy of Medical Sciences Springboard Grant, Dorothy Hodgkin Research Fellowship (DH130036/RG74249), MRC New Investigator Grant (MR/R022690/1/RG93186) and Lister Institute of Preventative Medicine Research Prize (RG93692). TN and AZ are supported by a Medical Research Council grant (MR/R02524X/1). HEJY was supported by an A*STAR International Fellowship from the Agency for Science, Technology and Research. KM was supported by UCLH Charity and the Mitchell Charitable Trust. SLH received funding for this work via an Academy of Medical Sciences Clinical Lecturer Starter Grant and the UCLH EGA Obstetric Charity. **Author contributions** HEJY, KM, SLH and ANSP designed the study. HEJY, KM, MABY, ESP collected and/or performed experiments. HEJY, KM, ESP and TN analysed and graphed the data. TN and AZ

provided predictive modelling analysis. HEJY, KM, TN, AZ, ALD, SLH and ANSP interpreted the data. HEJY, KM, SLH and ANSP wrote the paper. All authors performed final editing checks and approved the final manuscript.

References

519

520

- 521 1 Napso, T., Yong, H. E., Lopez-Tello, J. & Sferruzzi-Perri, A. N. The role of placental hormones in mediating maternal adaptations to support pregnancy and lactation. 522 523 Front Physiology 9:1091, doi:10.3389/fphys.2018.01091 (2018).
- 524 2 Burton, G. J., Fowden, A. L. & Thornburg, K. L. Placental Origins of Chronic Disease. 525 *Physiological reviews* **96**, 1509-1565, doi:10.1152/physrev.00029.2015 (2016).
- 526 3 Byrne, M. et al. Structure-function relationships in the feto-placental circulation 527 from in silico interpretation of micro-CT vascular structures. J Theor Biol 517, 528 110630, doi:10.1016/j.jtbi.2021.110630 (2021).
- 529 4 Aughwane, R. et al. Micro-CT and histological investigation of the spatial pattern of 530 feto-placental vascular density. Placenta 88, 36-43, 531 doi:10.1016/j.placenta.2019.09.014 (2019).
- 532 5 World Health, O. Every newborn: an action plan to end preventable deaths. 55 p. 533 (World Health Organization, 2014).
- 534 6 Lawn, J. E. et al. Every Newborn: progress, priorities, and potential beyond survival. 535 Lancet 384, 189-205, doi:10.1016/S0140-6736(14)60496-7 (2014).
- 536 7 Sharma, D., Shastri, S. & Sharma, P. Intrauterine Growth Restriction: Antenatal and 537 Postnatal Aspects. Clin Med Insights Pediatr 10, 67-83, doi:10.4137/CMPed.S40070 538 (2016).
- 539 8 Gordijn, S. J. et al. Consensus definition of fetal growth restriction: a Delphi 540 procedure. Ultrasound Obstet Gynecol 48, 333-339, doi:10.1002/uog.15884 (2016).
- 541 9 Van den Berg, B. J. & Yerushalmy, J. The relationship of the rate of intrauterine 542 growth of infants of low birth weight to mortality, morbidity, and congenital 543 anomalies. J Pediatr 69, 531-545, doi:10.1016/s0022-3476(66)80038-0 (1966).
- 544 Bianchi, M. E. & Restrepo, J. M. Low Birthweight as a Risk Factor for Non-10 545 communicable Diseases in Adults. Front Med (Lausanne) 8, 793990, 546 doi:10.3389/fmed.2021.793990 (2021).
- 547 11 Caradeux, J., Martinez-Portilla, R. J., Basuki, T. R., Kiserud, T. & Figueras, F. Risk of 548 fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent 549 or reversed end-diastolic velocities before 34 weeks of gestation: a systematic 550 review and meta-analysis. Am J Obstet Gynecol 218, S774-S782 e721, 551 doi:10.1016/j.ajog.2017.11.566 (2018).
- 552 Ishihara, N. et al. Increased apoptosis in the syncytiotrophoblast in human term 12 553 placentas complicated by either preeclampsia or intrauterine growth retardation. 554 Am J Obstet Gynecol 186, 158-166, doi:10.1067/mob.2002.119176 (2002).
- 555 13 Mayhew, T. M., Wijesekara, J., Baker, P. N. & Ong, S. S. Morphometric evidence that 556 villous development and fetoplacental angiogenesis are compromised by 557 intrauterine growth restriction but not by pre-eclampsia. Placenta 25, 829-833, 558 doi:10.1016/j.placenta.2004.04.011 (2004).
- 559 Macara, L. et al. Structural analysis of placental terminal villi from growth-restricted 14 560 pregnancies with abnormal umbilical artery Doppler waveforms. Placenta 17, 37-48, 561 doi:10.1016/s0143-4004(05)80642-3 (1996).
- 562 15 Teasdale, F. & Jean-Jacques, G. Intrauterine growth retardation: morphometry of the 563 microvillous membrane of the human placenta. *Placenta* **9**, 47-55 (1988).

564	16	Burton, G. J. & Fowden, A. L. The placenta: a multifaceted, transient organ. <i>Philos</i>
565		Trans R Soc Lond B Biol Sci 370 , 20140066, doi:10.1098/rstb.2014.0066 (2015).

- 566 17 Chavatte-Palmer, P. & Tarrade, A. Placentation in different mammalian species. Ann 567 Endocrinol (Paris) 77, 67-74, doi:10.1016/j.ando.2016.04.006 (2016).
- 568 18 Pere, M. C. Materno-foetal exchanges and utilisation of nutrients by the foetus: 569 comparison between species. Reprod Nutr Dev 43, 1-15, doi:10.1051/rnd:2003002 570 (2003).
- 571 Crawford, M. A., Hassam, A. G. & Williams, G. Essential fatty acids and fetal brain 19 572 growth. Lancet 1, 452-453, doi:10.1016/s0140-6736(76)91476-8 (1976).
- 573 20 Gresham, E. L., Simons, P. S. & Battaglia, F. C. Maternal-fetal urea concentration 574 difference in man: metabolic significance. J Pediatr 79, 809-811, doi:10.1016/s0022-575 3476(71)80396-7 (1971).
- 576 21 Sferruzzi-Perri, A. N. et al. Placental-specific Igf2 deficiency alters developmental 577 adaptations to undernutrition in mice. Endocrinology 152, 3202-3212, 578 doi:10.1210/en.2011-0240 (2011).
- 579 22 Sferruzzi-Perri, A. N. et al. An obesogenic diet during mouse pregnancy modifies 580 maternal nutrient partitioning and the fetal growth trajectory. Faseb J 27, 3928-581 3937, doi:10.1096/fj.13-234823 (2013).
- 582 23 Vaughan, O. R., Sferruzzi-Perri, A. N. & Fowden, A. L. Maternal corticosterone regulates nutrient allocation to fetal growth in mice. The Journal of physiology 590, 583 584 5529-5540 (2012).
- 585 24 Higgins, J. S., Vaughan, O. R., de Liger, E. F., Fowden, A. L. & Sferruzzi-Perri, A. N. 586 Placental phenotype and resource allocation to fetal growth are modified by the 587 timing and degree of hypoxia during mouse pregnancy. J Physiol 594, 1341-1356, 588 doi:10.1113/JP271057 (2015).
- 589 25 Napso, T., Hung, Y. P., Davidge, S. T., Care, A. S. & Sferruzzi-Perri, A. N. Advanced 590 maternal age compromises fetal growth and induces sex-specific changes in 591 placental phenotype in rats. Sci Rep 9, 16916, doi:10.1038/s41598-019-53199-x 592 (2019).
- 593 26 Lewis, R. M. & Sferruzzi-Perri, A. N. in Developmental Origins of Health and Disease 594 (eds L. Poston, K. M. Godfrey, M. A. Hanson, & P. Gluckman) (Cambridge University 595 Press).
- 596 27 Audette, M. C., McLaughlin, K. & Kingdom, J. C. Second Trimester Placental Growth 597 Factor Levels and Placental Histopathology in Low-Risk Nulliparous Pregnancies. J 598 Obstet Gynaecol Can 43, 1145-1152 e1141, doi:10.1016/j.jogc.2021.01.018 (2021).
- 599 28 Burton, G. J. et al. Optimising sample collection for placental research. Placenta 35, 600 9-22, doi:10.1016/j.placenta.2013.11.005 (2014).
- 601 29 Mayhew, T. M. Taking tissue samples from the placenta: an illustration of principles and strategies. Placenta 29, 1-14, doi:10.1016/j.placenta.2007.05.010 (2008). 602
- 603 Mayhew, T. M. Morphomics: An integral part of systems biology of the human 30 604 placenta. Placenta 36, 329-340, doi:10.1016/j.placenta.2015.01.001 (2015).
- 605 Salafia, C. M. et al. Placental surface shape, function, and effects of maternal and 31 606 fetal vascular pathology. Placenta 31, 958-962, doi:10.1016/j.placenta.2010.09.005 607
- 32 608 Gordon, Z. et al. Anthropometry of fetal vasculature in the chorionic plate. J Anat 609 **211**, 698-706, doi:10.1111/j.1469-7580.2007.00819.x (2007).

610	33	Heifetz, S. A. The umbilical cord: obstetrically important lesions. Clin Obstet Gynecol
611		39 , 571-587, doi:10.1097/00003081-199609000-00007 (1996).

- 612 34 Sferruzzi-Perri, A. N. & Camm, E. J. The programming power of the placenta.
- 613 Frontiers in Physiology **7:33**, doi:10.3389/fphys.2016.00033 (2016).
- 614 Vaughan, O. R. et al. Placenta-specific Slc38a2/SNAT2 knockdown causes fetal 35 615 growth restriction in mice. Clin Sci (Lond) 135, 2049-2066, doi:10.1042/CS20210575 616 (2021).
- 617 Luscher, B. P. et al. Placental glucose transporter (GLUT)-1 is down-regulated in 36 618 preeclampsia. Placenta 55, 94-99, doi:10.1016/j.placenta.2017.04.023 (2017).
- 619 37 Ganguly, A. et al. Glucose transporter isoform-3 mutations cause early pregnancy 620 loss and fetal growth restriction. American journal of physiology 292, E1241-1255 621 (2007).
- 622 38 Sferruzzi-Perri, A. N., Owens, J. A., Pringle, K. G. & Roberts, C. T. The neglected role 623 of insulin-like growth factors in the maternal circulation regulating fetal growth. The 624 Journal of physiology 589, 7-20 (2010).
- 625 39 Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental 626 phenotype and the insulin-like growth factors: resource allocation to fetal growth. 627 The Journal of physiology **595**, 5057-5093 (2017).
- Mifsud, W. & Sebire, N. J. Placental pathology in early-onset and late-onset fetal 628 40 629 growth restriction. Fetal Diagn Ther 36, 117-128, doi:10.1159/000359969 (2014).
- Brosens, I., Pijnenborg, R., Vercruysse, L. & Romero, R. The "Great Obstetrical 630 41 631 Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol 632 **204**, 193-201, doi:10.1016/j.ajog.2010.08.009 (2011).
- 633 42 Burton, G. J. & Jauniaux, E. Pathophysiology of placental-derived fetal growth 634 restriction. Am J Obstet Gynecol 218, S745-S761, doi:10.1016/j.ajog.2017.11.577 635 (2018).
- 636 43 Kovo, M. et al. Placental vascular lesion differences in pregnancy-induced 637 hypertension and normotensive fetal growth restriction. Am J Obstet Gynecol 202, 561 e561-565, doi:10.1016/j.ajog.2010.01.012 (2010). 638
- 639 Colson, A., Sonveaux, P., Debieve, F. & Sferruzzi-Perri, A. N. Adaptations of the 44 640 human placenta to hypoxia: opportunities for interventions in fetal growth 641 restriction. Hum Reprod Update, doi:10.1093/humupd/dmaa053 (2020).
- 642 45 Cindrova-Davies, T. & Sferruzzi-Perri, A. N. Human placental development and 643 function. Seminars in Cell and Developmental Biology In press (2022).
- 644 46 David, A. L. et al. Local delivery of VEGF adenovirus to the uterine artery increases 645 vasorelaxation and uterine blood flow in the pregnant sheep. Gene Ther 15, 1344-646 1350, doi:10.1038/gt.2008.102 (2008).
- 647 Sferruzzi-Perri, A. N. Regulating needs: Exploring the role of insulin-like growth 47 648 factor-2 signalling in materno-fetal resource allocation. Placenta Suppl 1, S16-S22, 649 doi:10.1016/j.placenta.2018.01.005 (2018).
- 650 Guo, L. et al. Altered gene expression and methylation of the human chromosome 48 651 11 imprinted region in small for gestational age (SGA) placentae. Dev Biol 320, 79-91, 652 doi:10.1016/j.ydbio.2008.04.025 (2008).
- 653 49 Yamaguchi, Y. et al. Placenta-specific epimutation at H19-DMR among common 654 pregnancy complications: its frequency and effect on the expression patterns of H19 655 and IGF2. Clin Epigenetics 11, 113, doi:10.1186/s13148-019-0712-3 (2019).

656	50	Antonazzo, P. et al. Placental IGF2 Expression in Normal and Intrauterine Growth
657		Restricted (IUGR) Pregnancies. Placenta 29, 99-101 (2008).

- 658 51 Janzen, C. et al. Placental glucose transporter 3 (GLUT3) is up-regulated in human 659 pregnancies complicated by late-onset intrauterine growth restriction. Placenta 34, 1072-1078, doi:10.1016/j.placenta.2013.08.010 (2013). 660
- 661 Desforges, M., Greenwood, S. L., Glazier, J. D., Westwood, M. & Sibley, C. P. The 52 662 contribution of SNAT1 to system A amino acid transporter activity in human 663 placental trophoblast. Biochem Biophys Res Commun 398, 130-134, 664 doi:10.1016/j.bbrc.2010.06.051 (2010).
- 665 53 Shibata, E. et al. Placental System A Amino Acid Transport is Reduced in Pregnancies With Small For Gestational Age (SGA) Infants but Not in Preeclampsia with SGA 666 667 Infants. Placenta 29, 879-882 (2008).
- 668 54 Lash, G. et al. Abnormal fetal growth is not associated with altered chorionic villous 669 expression of vascular endothelial growth factor mRNA. Mol Hum Reprod 7, 1093-670 1098, doi:10.1093/molehr/7.11.1093 (2001).
- 671 55 Lyall, F., Young, A., Boswell, F., Kingdom, J. C. & Greer, I. A. Placental expression of 672 vascular endothelial growth factor in placentae from pregnancies complicated by 673 pre-eclampsia and intrauterine growth restriction does not support placental 674 hypoxia at delivery. *Placenta* **18**, 269-276, doi:10.1016/s0143-4004(97)80061-6 675 (1997).
- 676 56 Andraweera, P. H., Dekker, G. A. & Roberts, C. T. The vascular endothelial growth 677 factor family in adverse pregnancy outcomes. Hum Reprod Update 18, 436-457, 678 doi:10.1093/humupd/dms011 (2012).
- 679 57 Krishnan, T. & David, A. L. Placenta-directed gene therapy for fetal growth 680 restriction. Semin Fetal Neonatal Med 22, 415-422, doi:10.1016/j.siny.2017.04.005 681 (2017).
- 682 58 Uhlen, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 683 1260419, doi:10.1126/science.1260419 (2015).
- 684 59 Human Protein Atlas Team. Human Protein Atlas - HNF1A in the placenta, https://www.proteinatlas.org/ENSG00000135100-HNF1A/tissue/placenta 685
- Ducat, A. et al. Low-dose aspirin protective effects are correlated with deregulation 686 60 687 of HNF factor expression in the preeclamptic placentas from mice and humans. Cell 688 *Death Discov* **5**, 94, doi:10.1038/s41420-019-0170-x (2019).
- 689 61 Rout, M. & Lulu, S. S. Molecular and disease association of gestational diabetes 690 mellitus affected mother and placental datasets reveal a strong link between insulin 691 growth factor (IGF) genes in amino acid transport pathway: A network biology 692 approach. J Cell Biochem, doi:10.1002/jcb.27418 (2018).
- 693 62 Brenner, W. E., Edelman, D. A. & Hendricks, C. H. A standard of fetal growth for the 694 United States of America. Am J Obstet Gynecol 126, 555-564, doi:10.1016/0002-695 9378(76)90748-1 (1976).
- 696 Mayhew, T. M. Stereology and the placenta: where's the point? -- a review. Placenta 63 697 **27 Suppl A**, S17-25, doi:10.1016/j.placenta.2005.11.006 (2006).

699

700

701 SUPPLEMENTARY INFORMATION

Supplementary Table 1: Full phenotype clinical data.

ID	Status	Medical history	Pregnancy complications	Maternal age quartile (years)	Ethnicity	Maternal booking BMI	Delivery mode	Gestat ion	Birthweight (g)	Infant sex	Placenta weight (g)	Placenta/ BW ratio (%)	Analysis comments
Control 1	Control			31-35	Asian	34	Vaginal delivery	39+6	3200	Male	442	13.8	
Control 2	Control			36-40	White	21	cat4 CS	39+1	3690	Female	516	14.0	
Control 3	Control			21-25	White	20	Vaginal delivery	39+0	3800	Female	534	14.1	
Control 4	Control			31-35	White	23	cat3 CS	41+1	3970	Male	509	12.8	
Control 5	Control			41-45	White	27	cat4 CS	39+1	3960	Female	481	12.1	
Control 6	Control			36-40	White	24	cat4 CS	39+1	2893	Female	413	14.3	
Control 7	Control			36-40	White	23	Vaginal delivery	39+0	3618	Male	491	13.6	
Control 8	Control			36-40	White	23	cat4 CS	39+1	3140	Male	398	12.7	
Control 9	Control			31-35	White	28	Vaginal delivery	39+5	3510	Male	526	15.0	
FGR 1	Late FGR			31-35	White	23	cat3 CS	37+0	1410	Male	160	11.3	

FGR 2	Late FGR	Hypothyroid		31-35	White	22	Vaginal delivery	37+5	2510	Female	346	13.8	
FGR 3	Late FGR	Migraines		31-35	Chinese	22	cat2 CS	37+2	2560	Male	380	14.8	
FGR 4	Late FGR		Low platelets	26-30	Afro Caribbean	22	cat2 CS	38+2	1985	Male	380	19.1	
FGR 5	Late FGR			31-35	Chinese	20	Vaginal delivery	39+4	2720	Female	360	13.2	
FGR 6	Late FGR		Gestational diabetes	31-35	Asian	38	cat1 CS	38+4	2396	Male	355	14.8	
FGR 7	Late FGR			36-40	Afro Caribbean	28	cat3 CS	39+0	2750	Male	404	14.7	Not run for qPCR

CS = caesarean section. Cat1 = Immediate threat to the life of the woman or fetus, Cat2 = Maternal or fetal compromise which is not immediately life-threatening, Cat3 = No maternal or fetal compromise but needs early birth, Cat4 = Birth timed to suit woman or healthcare provider. (NICE guideline 192: Caesarean birth, published 31 March 2021).

Supplementary Table 2: Morphological differences in the placenta by sampling location.

	Control (N=9)			FGR (N=7)			
	Central	Peripheral	P-value	Central	Peripheral	P-value	
Volume density (cm³/g)							
Intervillous space	0.39±0.02	0.36±0.01	0.130	0.36±0.02	0.35±0.02	0.577	
Stem villi	0.06±0.01	0.06±0.01	0.902	0.06±0.02	0.05±0.01	0.364	
Intermediate villi	0.1±0.01	0.13±0.01	0.105	0.08±0.01	0.08±0.01	0.720	
Terminal villi	0.42±0.02	0.42±0.02	0.941	0.41±0.03	0.38±0.03	0.526	
Syncytial knots	0.02±0.00	0.02±0.00	0.633	0.01±0.00	0.01±0.00	0.591	
Fibrosis	0.01±0.00	0.02±0.01	0.443	0.07±0.02	0.13±0.03	0.091	
Trophoblast	0.33±0.02	0.31±0.01	0.492	0.34±0.02	0.33±0.04	0.818	
Stromal	0.53±0.03	0.57±0.02	0.239	0.45±0.04	0.46±0.06	0.865	
Capillary	0.14±0.01	0.12±0.01	0.139	0.21±0.03	0.21±0.03	0.963	
Volume (cm ³)							
Intervillous space	187.75±10.19	171.7±9.96	0.277	121.96±11.52	116.92±10.14	0.748	
Stem villi	27.82±5.18	27.85±2.89	0.100	23.24±6.3	17.1±2.58	0.385	
Intermediate villi	49.91±4.81	60.89±5.94	0.170	24.77±2.83	26.19±2.23	0.700	
Terminal villi	199.23±8.7	202.24±13.7	0.855	141.08±17.48	129.51±15.51	0.630	
Syncytial knots	8.89±0.9	7.89±1.12	0.495	2.24±0.66	2.63±0.82	0.720	
Fibrosis	3.9±1.93	7.87±4.69	0.446	26.28±6.89	47.77±9.57	0.094	
Trophoblast	156.49±6.76	150.51±8.25	0.583	117.28±13.22	112.13±15.07	0.802	

Stromal	254.68±18.75	271.49±12.97	0.472	150.39±19.02	156.07±25.00	0.860
Capillary	67.72±5.88	56.89±5.04	0.181	73.05±14.18	72.51±13.58	0.979
Barrier thickness (µm)						
Arithmetic mean	2.84±0.08	2.82±0.10	0.885	2.84±0.19	2.86±0.18	0.940
Harmonic mean	2.14±0.07	2.15±0.07	0.918	2.24±0.15	2.24±0.14	0.987
Thickness uniformity index	1.33±0.02	1.31±0.02	0.508	1.47±0.08	1.48±0.08	0.936
Surface density (cm ² /cm ³)						
Villi	613.67±27.94	607.22±24.07	0.863	634.49±43.19	626.07±47.42	0.898
Fetal capillary	318.63±27.71	277.88±13.62	0.206	406.06±47.11	397.78±51.52	0.906
Surface area (m ²)						
Villi	15.32±0.97	15.99±0.92	0.622	10.87±1.63	10.3±1.51	0.801
Fetal capillary	7.89±0.75	7.32±0.44	0.519	7.11±1.31	6.67±1.2	0.807
Theoretical diffusion capacity	94.95±5.96	95.64±4.31	0.926	71.63±11.95	68.89±11.61	0.872
(cm ² /min/kPa)						
Specific diffusion capacity	27.15±1.86	27.24±1.23	0.968	30.24±4.58	28.7±3.71	0.798
(cm ² /min/kPa/g)						

Supplementary Table 3: Summary tables of errors in all 27 models for each patient.

	ONLY PERIPHERAL CONTRACTOR OF THE PERIPHERAL									
id scor	ccoro	STEREOLOGY & PCR			PCR			STEREOLOGY		
	score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
Control 1	0	0of4	0of4	0of4	1of4	1of4	1of4	0of4	0of4	0of4
Control 2	0	1of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4
Control 3	0	0of4	0of4	0of4	0of4	1of4	1of4	0of4	0of4	0of4
Control 4	0	0of4	0of4	0of4	4of4	3of4	3of4	0of4	0of4	0of4
Control 5	0	0of4	0of4	0of4	2of4	0of4	0of4	0of4	0of4	0of4
Control 6	0	0of4	0of4	0of4	3of4	3of4	4of4	0of4	0of4	0of4
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
Control 8	0	0of4	0of4	0of4	1of4	2of4	2of4	0of4	0of4	1of4
Control 9	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 1	1	4of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4
FGR 6	1	4of4	3of4	1of4	4of4	4of4	4of4	4of4	3of4	3of4


	ONLYCENTRAL										
id sc	score	STEREOLOGY & PCR			PCR			STEREOLOGY			
	score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	
Control 1	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
Control 2	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
Control 3	0	0of4	0of4	0of4	2of4	2of4	0of4	0of4	0of4	0of4	
Control 4	0	0of4	0of4	0of4	2of4	3of4	3of4	0of4	0of4	0of4	
Control 5	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
Control 6	0	3of4	2of4	1of4	3of4	3of4	3of4	0of4	0of4	0of4	
Control 7	0	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
Control 8	0	2of4	0of4	1of4	0of4	0of4	1of4	2of4	1of4	1of4	
Control 9	0	0of4	0of4	0of4	1of4	2of4	1of4	0of4	0of4	0of4	
FGR 1	1	1of4	0of4	0of4	4of4	4of4	4of4	0of4	0of4	0of4	
FGR 2	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
FGR 3	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
FGR 4	1	0of4	0of4	0of4	0of4	0of4	0of4	1of4	0of4	0of4	
FGR 5	1	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	0of4	
FGR 6	1	4of4	4of4	4of4	4of4	4of4	4of4	3of4	4of4	4of4	

	CENTRAL & PERIPHERAL									
id sco	score	STEREOLOGY & PCR			PCR			STEREOLOGY		
lu lu	Score	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet	xgbTree	glmnet	nnet
Control 1	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	0of8	0of8
Control 2	0	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
Control 3	0	0of8	0of8	0of8	1of8	2of8	2of8	0of8	0of8	0of8
Control 4	0	0of8	0of8	0of8	5of8	2of8	5of8	0of8	0of8	0of8
Control 5	0	0of8	0of8	0of8	2of8	0of8	0of8	0of8	0of8	0of8
Control 6	0	3of8	1of8	0of8	6of8	7of8	6of8	0of8	0of8	0of8
Control 7	0	0of8	0of8	0of8	0of8	0of8	0of8	1of8	0of8	0of8
Control 8	0	1of8	0of8	0of8	1of8	1of8	1of8	1of8	2of8	0of8
Control 9	0	1of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8
FGR 1	1	0of8	0of8	0of8	8of8	8of8	8of8	0of8	0of8	0of8
FGR 2	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
FGR 3	1	0of8	0of8	0of8	1of8	0of8	0of8	1of8	0of8	0of8
FGR 4	1	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8	0of8
FGR 5	1	0of8	0of8	0of8	0of8	1of8	1of8	0of8	0of8	0of8
FGR 6	1	8of8	7of8	5of8	8of8	8of8	8of8	6of8	7of8	7of8

Each cell for each patient and 27 models considered (different columns) indicates how many wrong predictions were made for this patient among all 4 or 8 available samples (for example, the entry 0of4 means that 0 errors were made among 4 predictions). The cell is highlighted in

red if at least one mistake was made for the patient. Third column in the first panel corresponds to the best model, using nnet ML algorithm, and both stereology and PCR data for peripheral samples. This model returns only one wrong prediction out of 60 samples considered.

Supplementary Figure 1: Different interdependencies of features for stereological data.



Different interdependencies of features for Control (blue colour) and FGR (red colour) on stereological data. Each point is a separate patient measurement, each line connects all measurements for each patient. For many pairs of features, a separation between FGR cases and controls was easily seen, hence, enabling a construction of a successful predictive model.